Apogee Therapeutics Inc Stock Price, News & Analysis

Apogee Therapeutics (Nasdaq: APGE) announced on October 8, 2025 that it has commenced a proposed underwritten public offering of shares of common stock or, for certain investors, pre-funded warrants to purchase common stock. The company said it will grant underwriters a 30-day option to buy up to an additional 15% overallotment of the shares at the public offering price, subject to market conditions and underwriting terms.

Apogee intends to use net proceeds together with existing cash and marketable securities to fund preclinical studies, clinical trials, manufacturing, commercial readiness for its antibody programs, additional R&D, capital expenditures, working capital and general corporate purposes. The offering will be made by written prospectus and is subject to completion and SEC registration requirements.

Apogee Therapeutics (NASDAQ:APGE) announced that data from its Phase 2 APEX trial of APG777 for moderate-to-severe atopic dermatitis will be presented at the EADV Congress 2025 in Paris. The presentation will highlight the drug's 16-week topline data, which successfully met primary and secondary endpoints.

APG777 stands out as the only biologic being tested for 3- and 6-month dosing intervals in maintenance treatment. The company will also present data on APG990 and their combination strategy with APG279, a coformulation designed to inhibit Type 1, Type 2, and Type 3 inflammation, potentially expanding their patient reach.

The presentations include a late-breaker oral session by Dr. Emma Guttman-Yassky and three poster presentations covering the APEX program, APG990's safety profile, and the combination therapy approach.

Apogee Therapeutics (Nasdaq: APGE) has announced its upcoming participation in the Stifel 2025 Virtual Immunology and Inflammation Forum. The company's management team will engage in a fireside chat scheduled for Tuesday, September 16, 2025, at 11:30 a.m. E.T.

Investors and interested parties can access both the live and archived versions of the fireside chat through the News & Events page in the Investors section of Apogee Therapeutics' website.

Apogee Therapeutics (NASDAQ:APGE) reported significant progress in its pipeline and Q2 2025 financial results. The company announced positive 16-week data from APEX Phase 2 Part A trial for APG777, their anti-IL-13 antibody for atopic dermatitis, meeting all primary and secondary endpoints. APG777 demonstrated 71.0% EASI reduction vs. 33.8% for placebo, with potential for 3-6 month maintenance dosing versus current bi-weekly standard.

Key developments include first patient dosing in Phase 1b head-to-head trial of APG279 versus DUPIXENT, accelerated APEX Phase 2 Part B readout to mid-2026, and ongoing progress with APG333. The company maintains a strong financial position with $621.2 million in cash, providing runway into Q1 2028, despite increased R&D expenses of $55.7 million and net loss of $66.1 million for Q2 2025.

Apogee Therapeutics (NASDAQ:APGE) announced positive 16-week data from Phase 2 APEX clinical trial of APG777, its anti-IL-13 antibody for moderate-to-severe atopic dermatitis. The trial achieved all primary and secondary endpoints, with APG777 demonstrating a 71.0% decrease in EASI from baseline at Week 16 and an EASI-75 response rate of 66.9% (42.5% placebo-adjusted), marking the highest efficacy of any biologic in a global study.

The drug showed rapid onset of itch relief and was well-tolerated with a favorable safety profile. Based on exposure-response relationships observed, APEX Part B is testing higher doses with readout accelerated to mid-2026. The company plans to initiate Phase 3 trials in 2026, while also conducting a head-to-head trial of APG279 versus DUPIXENT with results expected in 2H 2026.

Apogee Therapeutics (Nasdaq: APGE) has announced a conference call and webcast scheduled for July 7, 2025, at 8:00 a.m. ET to discuss Part A 16-week data from their Phase 2 APEX trial of APG777 in patients with moderate-to-severe atopic dermatitis.

The clinical-stage biotechnology company, which focuses on developing novel biologics for inflammatory and immunology conditions, will present results for APG777, their candidate targeting atopic dermatitis, asthma, eosinophilic esophagitis (EoE), and chronic obstructive pulmonary disease (COPD). The webcast will be accessible through the company's website, with a replay available after the presentation.

Apogee Therapeutics (NASDAQ: APGE) has announced its upcoming participation in the Jefferies Global Healthcare Conference. The company's management team will engage in a fireside chat scheduled for Thursday, June 5, 2025, at 10:30 a.m. ET. Interested parties can access both live and archived versions of the presentation through the News & Events page in the Investors section of Apogee's website.

Apogee Therapeutics (NASDAQ: APGE) reported Q1 2025 financial results and pipeline updates. The company's lead candidate APG777 is advancing in Phase 2 APEX trial for atopic dermatitis, with interim data expected mid-2025. Recent market research shows strong preference for APG777's quarterly dosing, with 96% of current biologic patients likely to switch. The company reported $681.4 million in cash reserves, extending runway into Q1 2028. Key developments include: first patient dosed in APG777's Phase 1b asthma trial, positive interim results for APG808 in asthma showing 53% FeNO reduction, and plans to initiate APG279 head-to-head trial vs DUPIXENT in 2025. Financial results showed R&D expenses of $46.4 million and a net loss of $55.3 million for Q1 2025.

Apogee Therapeutics (NASDAQ: APGE) announced positive interim results from its Phase 1b trial of APG808, a novel half-life extended IL-4Rα antibody, in patients with mild-to-moderate asthma. The trial, involving 22 adult patients, demonstrated that APG808 achieved a 53% maximal decrease in FeNO (a biomarker of Type 2 inflammation) from baseline, with a sustained 50% decrease at 12 weeks. The drug showed a favorable safety profile with no Grade 3 TEAEs or severe adverse events. Most common side effects included headache, injection site erythema, and upper respiratory tract infections. Notably, APG808's optimized formulation and pharmacokinetic profile support potential dosing every 2 months or longer, compared to the current biweekly standard of care, potentially offering a significant advancement in asthma treatment.